Six months into the COVID-19 pandemic, what have we learned about the risks to those living with neuroendocrine cancer? Does a cancer diagnosis or cancer treatment increase a person’s risk for serious illness from COVID-19?
NETRF Chief Executive Officer Elyse Gellerman sat down with Mark Lewis, MD, oncologist, Intermountain Healthcare, and NETRF Board Member to take a look back and a look forward at pandemic developments.
The discussion offers the latest information on how to protect yourself from COVID-19 during routine activities like grocery shopping, dining out, and managing returns to work or school.
Mentioned in this interview
- Washington Post. Don’t panic about getting shopping or package delivery.
- National Institutes of Health. Coronavirus stable on surfaces for hours.
- New England Journal of Medicine: Surface durability of COVID-19.
- The Lancet: Clinical impact of COVID-19 on patients with cancer (CCC19).
- The Scientist: Publications make retractions.
Explore other COVID-19 and NETs topics
- Managing a somatostatin analog injection schedule during COVID-19.
- COVID-19 precautions for those living with cancer.
- NETWise podcast – COVID-19 and NETs: What you need to know.
- Expert video interview: Managing emotional aspects of social distancing.
- NETWise podcast – The increasing role of telemedicine in cancer care.
Staying up-to-date on COVID-19
The COVID-19 outbreak is rapidly changing. Aspects of the content may have changed since it was published. To stay abreast of the situation, follow these trusted resources for the latest information:
Netrf.org terms and conditions: This information is not intended as and shall not be relied upon as medical advice. The Neuroendocrine Tumor Research Foundation encourages all users to discuss any information found here with their oncologist, physician, and/or an appropriate qualified health professional.